[A multi-center retrospective study of L-asparaginase-based regimens as first-line treatment in newly diagnosed extranodal NK/T-cell lymphoma].

Abstract

OBJECTIVE:

To analyze the short-term efficacy, overall survival (OS), and safety in newly diagnosed extranodal NK/T-cell lymphoma (ENKTL) patients with L-asparaginase based regimens or CHOP regimen in combination with radiotherapy as first-line treatment.

METHODS:

Of the total 181 patients diagnosed by imaging and pathology, 69 patients received CHOP regimen and 112 patients received L-asparaginase based regimens. All the patients received radical radiotherapy(RT)after 6 cycles of chemotherapy.

RESULTS:

The overall response rates of L-asparaginase-based group and CHOP group were 90.2% and 72.5%, respectively (P=0.002). The 1, 2, 5-year OS and progression-free survival (PFS) in L-asparaginase-based group were 96.0%, 88.3%, 65.1% and 94.2%, 79.8%, 50.0%, respectively. The 1, 2, 5-year OS and PFS in CHOP group were 82.6%, 61.9%, 28.4% and 63.8%, 44.0%, 21.0% (P=0.000).

CONCLUSION:

Compared with CHOP regimen, L-asparaginase-based chemotherapy is more effective and safe for newly diagnosed nasal-type ENKTL.

• Authors: Fangfang Yuan, Xudong Wei, Qingsong Yin, Yufu Li, Ruihua Mi, Hao Ai, Haiping Yang, Hongyi Li, Shoubei Ge, Yanyan Liu, Yongping Song
• Journal: Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi (Zhonghua Xue Ye Xue Za Zhi) Vol. 35 Issue 7 Pg. 614-8 (Jul 2014) ISSN: 0253-2727 [Print] China
• PMID: 25052604 (Publication Type: English Abstract, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)

Chemical References

• Vincristine
• Doxorubicin
• Cyclophosphamide
• Asparaginase
• Prednisone

Topics

• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Asparaginase (administration & dosage)
• Cyclophosphamide (therapeutic use)
• Doxorubicin (therapeutic use)
• Female
• Humans
• Lymphoma, Extranodal NK-T-Cell (drug therapy)
• Male
• Middle Aged
• Prednisone (therapeutic use)
• Retrospective Studies
• Treatment Outcome
• Vincristine (therapeutic use)